Fus s I3596* is a 65 kDa major glycoprotein allergen derived from Fusarium solani, a soil-borne fungal pathogen implicated in both plant diseases and human allergies . While F. solani f. sp. pisi specifically infects pea plants (Pisum sativum), Fus s I3596* is associated with broader allergenic responses in humans, particularly in individuals with asthma or nasobronchial allergies .
Structure: Glycoprotein with sequential cleavage sites for trypsin and cyanogen bromide (CNBr), yielding 11 peptide fragments (I–XI) .
Key epitopes: Peptide IV-1 (from peak IV) demonstrates high IgE-binding capacity .
| Peptide | IgE Reactivity | Histamine Release | Therapeutic Potential |
|---|---|---|---|
| IV-1 | High | None | Blocks histamine release when pre-incubated |
| I, III, V | Moderate-High | Yes | Limited utility |
Prevalence: Reacts with 95% of Fusarium-sensitive patients .
Mechanism: Binds IgE antibodies but does not trigger histamine release in vitro or intradermal responses in vivo .
Cross-reactivity: Shares allergenic components with other Fusarium species, including proteins at 24 kDa, 58.5 kDa, and 97 kDa .
Immunotherapy: Peptide IV-1 inhibits histamine release in a dose-dependent manner when pre-incubated with patient blood samples, suggesting utility in hyposensitization therapies .
Safety profile: Non-anaphylactic nature reduces risk during treatment .
Recombinant expression: Current studies focus on native Fus s I3596*; recombinant forms remain uncharacterized in the literature .
Host-pathogen overlap: While F. solani f. sp. pisi causes pea root rot , its relationship to human allergenic proteins like Fus s I3596* is unexplored.
Genomic insights: Transcriptomic studies of F. solani f. sp. pisi highlight fungal strategies to evade plant defenses (e.g., DNase-mediated nuclear DNA digestion) , but parallels to human immune evasion are unknown.